ERBB2 and non-small cell lung carcinoma: The preliminary result of the ongoing MyPathway trial of trastuzumab and pertuzumab, targeting HER-2 dimerization, reported an ORR of 13 and 19% in 16 HER-2-amplified and 12-mutated NSCLC patients, respectively (55).